Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 5/20 | 0.38 |
| ▸ | SLC2A2 | P11168 | 3/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.31 |
| ▸ | CNR1 | P21554 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3392032 | 0.86 | MAPT (0.35) | SLC2A1TRPA1 | |
| SCHEMBL3395134 | 0.82 | MAPK14 (0.35) | MAPK14 | |
| SCHEMBL14632158 | 0.81 | GAA (0.30) | MAPK14 | |
| SCHEMBL3360406 | 0.80 | MEN1 (0.41) | CRHR1SLC2A2DPP4MAPK14TRPA1 | |
| SCHEMBL3395179 | 0.80 | TRPA1 (0.38) | CRHR1SLC2A2DPP4MAPK14TRPA1 | |
| SCHEMBL3397222 | 0.78 | MAPK14 (0.34) | MAPK14 | |
| SCHEMBL3396264 | 0.77 | CRHR1 (0.38) | CRHR1SLC2A2DPP4MAPK14TRPA1 | |
| SCHEMBL3393708 | 0.76 | ALDH1A1 (0.31) | — | |
| SCHEMBL1691532 | 0.73 | SLC2A2 (0.47) | SLC2A2DPP4SLC2A1 | |
| SCHEMBL14632155 | 0.71 | EGLN2 (0.39) | CRHR1DPP4SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150239905-A1 | IMIDAZOPYRIDINE COMPOUNDS | BIOVITRUM AB (PUBL) (SE) | 2015-08-27 | — | — | US | disclosed |
| US-20140206662-A1 | Imidazopyridine Compounds | PROXIMAGEN LTD. (GB) | 2014-07-24 | — | — | US | disclosed |
| EP-2376490-B1 | IMIDAZOPYRIDINE COMPOUNDS | PROXIMAGEN LTD (GB) | 2013-01-23 | — | — | EP | disclosed |
| WO-2010064020-A1 | IMIDAZOPYRIDINE COMPOUNDS | PROXIMAGEN LTD. (GB) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239905-A1 | IMIDAZOPYRIDINE COMPOUNDS | SSB, MIF, IDO1 | CRHR1 4422/4885SLC2A2 1914/4885DPP4 307/4885 |
| US-20140206662-A1 | Imidazopyridine Compounds | SSB, NFKBIA, TPMT | CRHR1 4208/4885SLC2A2 2135/4885DPP4 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.